Navigation Links
Reportlinker Adds Biomarkers - Technologies, Markets and Companies
Date:6/3/2010

Clinical trials of HCV therapeutics 182

Limitations to the development of effective anti-HCV therapeutics 183

Causes of treatment failure in chronic hepatitis C 183

HCV drug resistance 183

Personalized management of HCV infection 183

Future needs in HCV therapy 184

Summary and concluding remarks 185

10. Miscellaneous Commercially Important Virus Infections 187

Introduction 187

Herpes viruses 187

Herpes simplex virus 187

Treatment of HSV-1 187

Acyclovir 187

Vaccine for HSV 188

Antisense therapy for HSV-1 188

Herpes simplex virus 2 and genital herpes 188

Famciclovir 189

Intravaginal microbicidal agents for HSV-2 189

Vaccine for HSV-2 189

Herpes simplex keratitis 190

Herpes simplex encephalitis 190

Limitations of current HSV therapies 191

Herpes zoster virus 191

Herpes zoster and chicken pox 191

Epidemiology of herpes zoster 191

Treatment of herpes zoster 191

Herpes zoster vaccine 192

Cytomegalovirus 192

Valganciclovir hydrochloride 192

T-cell therapy for CMV 193

Vaccine for CMV 193


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Reportlinker Adds Future of Red Biotechnology in China
2. Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
3. Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
4. Reportlinker Adds SNP Genotyping and Analysis Markets
5. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
6. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
7. Reportlinker Adds Biotechnology Instrumentation - International Market Trends
8. Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective
9. Reportlinker Adds Pharmacodynamic Assays
10. Reportlinker Adds Neurostimulation - A Global Market Perspective
11. Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrine therapy and oncology, today announced the opening ... with cetrorelix pamoate for the treatment of benign prostatic ... more than 20 million men in the U.S. alone. ...
... ATLANTA, Georgia, June 10 , ... Elsevier / MC Strategies, a pioneer in ... to announce that five,Clinical e-Learning courses were named as winners ... International,Academy of the Visual Arts (IAVA). With thousands of entries ...
... , Three-of-Four Patients Surveyed Experience Daily Pain From ... the European League Against Rheumatism Annual Congress of ... Results from the Rheumatoid Arthritis: Insights, Strategies ... rheumatoid arthritis (RA) patients throughout Europe and Canada ...
Cached Biology Technology:AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 5Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 2Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 3Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 2New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 3New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 5New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 6
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... CHICAGO , Sept. 16, 2013  AUTOTESTCON –  Marvin ... Systems ), a trusted provider of innovative test solutions ... company,s involvement in AUTOTESTCON 2013 . The 49th ... Chicago, Illinois for ATE leaders ...
... A new understanding of the essential role of gut microbes ... with some of the more significant health problems facing people ... a new analysis. Problems ranging from autoimmune disease to ... to immune dysfunction that begins with a "failure to communicate" ...
... He heads the Institute for Diabetes and Obesity (IDO) ... director of the Helmholtz Diabetes Center (HDC). The Alexander ... Diseases at the Technische Universitt Mnchen (TUM). His research ... of fat and sugar metabolism, with the objective of ...
Cached Biology News:Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 2Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 3Gut microbes closely linked to proper immune function, other health issues 2Gut microbes closely linked to proper immune function, other health issues 3